Transformational Therapies Targeting Protein Degradation
Pioneering Tuneable Small-Molecule Degradation Platform
Dunad Therapeutics is focusing on the development of next-generation targeted protein degradation therapies. Dunad’s platform enables selective degradation via direct target modification using tuneable mono-valent small molecules, unlocking new target space and allowing for the development of more drug-like, orally bioavailable and CNS-accessible protein degraders.
Dunad’s unique small molecule platform induces targeted degradation of disease-causing proteins via direct modulation of the target protein’s surface topology. The Company’s novel molecular approach, based on mono-valent small molecules, is fully tuneable to be exquisitely selective for the target, and is underpinned by a target-class agnostic mechanism of action that is distinct from traditional mechanisms of targeted protein degradation.
The Company’s drug pipeline is powered by its expanding 4-pillar proprietary platform:
Expanding the frontiers of our plug-and-play mono-valent degrader platform
Accelerating Hit ID against novel
Proprietary Screening Library
Unlocking previously inaccessible degradation targets via global and multi-dimensional profiling of the proteome
Driving the best drug candidates through the development
Dunad is focusing on targets for which degradation is the optimal mechanism of action, and inhibition of the target’s activity alone is insufficient to elicit the maximum therapeutic effect.
While the unique MOA and compositions of our platform are expected to unlock access to the previously undruggable targets, our platform also enables development of orally bioavailable and CNS-accessible degrader therapeutics, together expanding the frontiers of protein degradation space.
Dunad is continuing to expand its world-class scientific team with expertise across protein degradation, covalent therapeutics and proteomics, as well as it’s business leadership team. If you are interested in joining our team of passionate innovators, email firstname.lastname@example.org
PATRICK GUNNING, PhD
Founder, acting CEO, CSO
DIANA KRASKOUSKAYA, PhD
GRAHAM SIMPSON, PhD
Chief Financial Officer
ELIZABETH ROPER, PhD
BERNHARD KUSTER, PhD
IAN COLLINS, PhD
JEFF KEILLOR, PhD
Targeted Covalent Therapeutics
MIKE MAZANETZ, PhD
PETER HUNT, PhD
JANE DANCER, PhD
Business Development Adviser
Dunad is backed by Epidarex Capital, a leading transatlantic venture capital firm with a track record of building exceptional life science companies in emerging hubs in the US and UK. For more information, visit www.epidarex.com.